-- 根據週一提交給印度證券交易所的文件顯示,Cohance Lifesciences(NSE:COHANCE,BOM:543064)任命Umang Vohra為董事長兼集團首席執行官,自5月1日起生效。 他接替了Vivek Sharma的職位,他已卸任執行董事長兼董事,並於4月30日起被重新任命為公司特別顧問。 該公司股價在近期交易中上漲了20%。
Related Articles
Dongjiang Environmental's Loss Widens 2.7% in Q1
Dongjiang Environmental (HKG:0895, SHE:002672) recorded an attributable loss of 150.2 million yuan in the first quarter of 2026, 2.7% wider than 146.3 million yuan a year prior, according to a Monday Hong Kong bourse filing.Loss per share widened to 0.14 yuan from 0.13 yuan in the corresponding period of the previous fiscal year.The waste disposal management company's revenue from operations declined 13% to 602.6 million yuan from 695.9 million yuan in the year-ago period.
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
Health care stocks were edging higher pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2% and the iShares Biotechnology ETF (IBB) marginally advancing.Organon (OGN) has agreed to be acquired by Sun Pharmaceutical Industries for $14 per share in an all-cash deal with an $11.75 billion enterprise valuation, the companies said. Shares of Organon were up more than 17% premarket.Oruka Therapeutics (ORKA) stock was up more than 34% after the company said 63.5% of patients treated with ORKA-001 achieved the primary endpoint of complete skin clearance at week 16 in a phase 2a trial in moderate-to-severe plaque psoriasis.Ligand Pharmaceuticals (LGND) shares were up more than 3% after the company said it has agreed to purchase biotechnology peer Xoma Royalty (XOMA) in an all-cash deal valued at roughly $739 million.
Zuoli Kechuang Logs Drop in Q1 Profit
Zuoli Kechuang Micro-finance Company (HKG:6866) recorded a decline in attributable profit in the first quarter of 2026 to 13.6 million yuan from 14.8 million yuan a year prior, according to a Monday Hong Kong bourse filing.Net interest income for the three months slipped to 28.4 million yuan from 35.2 million yuan in the year-ago period.